UK's Hikma posts higher annual revenue on strong injectables segment
26/02/2026 07:18
Feb 26 (Reuters) - Hikma Pharmaceuticals HIK.L reported higher annual revenue on Thursday, driven by strong performance in its injectables division and robust demand across its key markets. The company's 2025 revenue came in at $3.35 billion, compared with $3.13 billion in 2024. (Reporting by Sri Hari N S in Bengaluru; Editing by Sumana Nandy) ((SriHari.NS@thomsonreuters.com;))